PR Newswire

The newsfeed available here is provided by our content partner PR Newswire. This is one of the most important and widest-reaching press services, providing news, press releases and multimedia content to the media, journalists and the public.
The NewsWire Hub ("X-Billboard") currently comprises four of the most important international news sources and is supplemented by a stock market information service. The individual newswire services complement each other and provide a complementary range of information, more than three quarters of the official news sources on which editors worldwide base their stock market reporting. Your advantage: You will find everything here in one overview. You can navigate to the individual sections using the control elements. In the terminal view, you can carry out individual searches at company level.
presented by
N
More Tools & Gadgets
F&G: 56
5.974,72 S&P · 21,00 Vola-Index · 103.543,31 BTC · 1,15225 EURUSD
System-State: Number of processed items 103.919 Notifications successully processed since Inception
EXCHANGE NEWSBOARD
                              
NEWSWIRE INFOBOARD
                              
PR Newswire is an important news source that can be accessed via the X-Billboard. It is part of the Newswire Hub, which bundles important international news sources for stock market participants in one central location. If you want to get a quick overview, you can easily scroll through the headlines. If you want to look at the news in more detail, you can use the detailed views of the info cards to directly access the respective news item and other analysis tools.
NEWS
EXPLORER
US7711951043
State: 21.06.2025 | 10AM
Do you already know our new terminal view? Click here.
FIGI: BBG000BQYMR4
RHHBY
Roche Holding AG (ADR)
GICS: - · Sector: Healthcare · Sub-Sector: Drug Manufacturers—General
NAME
Roche Holding AG (ADR)
ISIN
US7711951043
TICKER
RHHBY
MIC
XOTC
REUTERS
RHHBY.PK
BLOOMBERG
RHHBY US
Mon, 12.05.2025       Roche Holding
US7711951043

An investment of up to $550 million by 2030 will establish the Indianapolis site as a hub for manufacturing of Roche's continuous glucose monitoring solution.Expansion will create hundreds of jobs while also enhancing U.S. production capabilities.Increased access to diabetes management tools will help improve health outcomes for patients in the U.S. and globally.

INDIANAPOLIS, May 12, 2025 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today it plans to invest up to $550 million in its Diagnostics site in Indianapolis by 2030. The site will become a major hub for the manufacturing of Roche's continuous glucose monitoring (CGM) systems – marking a new milestone in Roche's long history of revolutionizing healthcare across the globe.

Read More
Roche Holding
Technical Analysis Termsheet Terminal
Permalink
Mon, 13.01.2025       Roche Holding
US7711951043

The VENTANA Kappa and Lambda Dual ISH mRNA Probe Cocktail assay is the first clinically approved in-situ hybridisation (ISH) test with the sensitivity to assess the full spectrum of B-cell lymphoma subtypes.1,2 The test helps differentiate a B-cell cancer from a normal, reactive immune response, offering diagnostic certainty for healthcare providers and their patients. B-cell lymphoma accounts for approximately 85 percent of non-Hodgkin lymphoma (NHL) cases, which is one of the most common cancers in the US.3
Read More
Roche Holding
Technical Analysis Termsheet Terminal
Permalink
Thu, 09.01.2025       Roche Holding
US7711951043

The VENTANA DP 600 slide scanner, part of Roche's Digital Pathology Dx system, is now cleared by the FDA to aid in clinical diagnosis, enabling pathologists to diagnose patients using digital images.This 240-slide scanner produces excellent image quality of stained histology slides from patient tissue samples, while providing ease-of-use and workflow flexibility for the pathology lab.Primary diagnosis in digital pathology helps enhance diagnostic accuracy, consistency, and speed by providing high-resolution images and advanced analysis tools.
Read More
Roche Holding
Technical Analysis Termsheet Terminal
Permalink
Silent Ad
Mon, 25.11.2024       Roche Holding
US7711951043

The PATHWAY HER2 (4B5) test helps to identify patients with previously-treated, unresectable or metastatic HER2-positive biliary tract cancer (BTC) who may be eligible for treatment with ZIIHERA.There are currently very few options for BTC patients as most cases are at an advanced stage at the time of diagnosis.This approval represents a new indication for Roche's existing PATHWAY HER2 (4B5) test and expands its clinical utility by broadening the scope of patients who are eligible for HER2-targeted therapies.
Read More
Roche Holding
Technical Analysis Termsheet Terminal
Permalink
Mon, 18.11.2024       Roche Holding
US7711951043

The VENTANA FOLR1 (FOLR1-2.1) RxDx Assay detects the folate receptor 1 protein (FOLR1 or FRɑ), which is over-expressed in most ovarian cancers.The test identifies ovarian cancer patients eligible for targeted treatment with ELAHERE.This certification follows the unprecedented decision by regulators to grant an early exemption approval for the test in Germany and Austria earlier this year.

TUCSON, Ariz., Nov. 18, 2024 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received CE Mark for its VENTANA® FOLR1 (FOLR1-2.1) RxDx Assay. This is the first immunohistochemistry (IHC) companion diagnostic test to be made widely available in Europe to aid in identifying epithelial ovarian cancer (EOC) patients who may be eligible for targeted treatment with ELAHERE® (mirvetuximab soravtansine). ELAHERE is a first-in-class antibody-drug conjugate (ADC) therapy developed by AbbVie for the treatment of FRɑ-positive platinum-resistant ovarian cancer.

Read More
Roche Holding
Technical Analysis Termsheet Terminal
Permalink
Mon, 18.11.2024       Roche Holding
US7711951043

The VENTANA FOLR1 (FOLR1-2.1) RxDx Assay detects the folate receptor 1 protein (FOLR1 or FRɑ), which is over-expressed in most ovarian cancers.The test identifies ovarian cancer patients eligible for targeted treatment with ELAHERE.This certification follows the unprecedented decision by regulators to grant an early exemption approval for the test in Germany and Austria earlier this year.

TUCSON, Ariz., Nov. 18, 2024 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received CE Mark for its VENTANA® FOLR1 (FOLR1-2.1) RxDx Assay. This is the first immunohistochemistry (IHC) companion diagnostic test to be made widely available in Europe to aid in identifying epithelial ovarian cancer (EOC) patients who may be eligible for targeted treatment with ELAHERE® (mirvetuximab soravtansine). ELAHERE is a first-in-class antibody-drug conjugate (ADC) therapy developed by AbbVie for the treatment of FRɑ-positive platinum-resistant ovarian cancer.

Read More
Roche Holding
Technical Analysis Termsheet Terminal
Permalink
Tue, 12.11.2024       Roche Holding
US7711951043

Collaboration will leverage Flare Therapeutics' proteomic and mass spectrometry platform and expertise, powered by its proprietary library of electrophilic compounds, to discover novel small molecules aimed at transcription factor targets in oncology

Flare Therapeutics to receive US$70 million upfront, and potential milestone payments exceeding US$1.8 billion, as well as royalties

CAMBRIDGE, Mass., Nov. 12, 2024 /PRNewswire/ -- Flare Therapeutics Inc., a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for oncology and other therapeutic areas, today announced it has entered into a strategic discovery collaboration with Roche (SIX: RO, ROG; OTCQX: RHHBY). This partnership will leverage Flare Therapeutics' proteomic and mass spectrometry platform and expertise, powered by its proprietary library of electrophilic compounds, to discover novel small molecule drugs aimed at previously undrugged transcription factor targets in oncology.

Read More
Roche Holding
Technical Analysis Termsheet Terminal
Permalink
Fri, 18.10.2024       Roche Holding
US7711951043

The new VENTANA CLDN18 (43-14A) RxDx Assay helps fulfil an unmet medical need by enabling clinicians to identify patients with gastric or gastroesophageal junction (GEJ) cancer who may benefit from a targeted treatment option. CLDN18.2 is an emerging biomarker in gastric and GEJ cancers and helps predict the likelihood of response to targeted therapy.As the leader in companion diagnostics, Roche continues to build on its commitment to improve personalised healthcare to enable better patient outcomes.
Read More
Roche Holding
Technical Analysis Termsheet Terminal
Permalink
Tue, 08.10.2024       Roche Holding
US7711951043

Survey findings from over 8,700 people in 12 countries show that half of those polled have inadequate understanding of HPV, with nearly one-third being unsure or unaware of it altogether.1Findings also show that significant barriers continue to exist that are preventing women from seeking screening.1However, more than 70% of the respondents indicated they would be interested in the option of collecting their own sample for screening if available.

TUCSON, Ariz., Oct. 8, 2024 /PRNewswire/ -- GWI research commissioned by Roche (SIX: RO, ROG; OTCQX: RHHBY) and carried out across 12 countries in Latin America and Europe has revealed that half of those polled have either limited or no awareness of the important role human papillomavirus (HPV) plays in cervical cancer.1

Read More
Roche Holding
Technical Analysis Termsheet Terminal
Permalink
Tue, 08.10.2024       Roche Holding
US7711951043

Survey findings from over 8,700 people in 12 countries show that half of those polled have inadequate understanding of HPV, with nearly one-third being unsure or unaware of it altogether.1Findings also show that significant barriers continue to exist that are preventing women from seeking screening.1However, more than 70% of the respondents indicated they would be interested in the option of collecting their own sample for screening if available.

TUCSON, Ariz., Oct. 8, 2024 /PRNewswire/ -- GWI research commissioned by Roche (SIX: RO, ROG; OTCQX: RHHBY) and carried out across 12 countries in Latin America and Europe has revealed that half of those polled have either limited or no awareness of the important role human papillomavirus (HPV) plays in cervical cancer.1

Read More
Roche Holding
Technical Analysis Termsheet Terminal
Permalink
Silent Ad
Mon, 09.09.2024       Roche Holding
US7711951043

The Roche Digital Pathology Open Environment brings together a wide array of innovative AI-based pathology tools to help clinicians improve patient care and expand personalised healthcare.Roche is now integrating more than 20 artificial intelligence (AI) algorithms from eight new collaborators into its digital pathology open environment.AI technology helps enhance pathology with high value insights, which can benefit cancer patients through precision medicine leading to targeted treatment.

TUCSON, Ariz., Sept. 9, 2024 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the expansion of its digital pathology open environment with the integration of more than 20 advanced artificial intelligence (AI) algorithms from eight new collaborators. These strategic collaborations aim to support pathologists and scientists in cancer research and diagnosis by leveraging cutting-edge AI technology.

Read More
Roche Holding
Technical Analysis Termsheet Terminal
Permalink
Mon, 09.09.2024       Roche Holding
US7711951043

The Roche Digital Pathology Open Environment brings together a wide array of innovative AI-based pathology tools to help clinicians improve patient care and expand personalised healthcare.Roche is now integrating more than 20 artificial intelligence (AI) algorithms from eight new collaborators into its digital pathology open environment.AI technology helps enhance pathology with high value insights, which can benefit cancer patients through precision medicine leading to targeted treatment.

TUCSON, Ariz., Sept. 9, 2024 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the expansion of its digital pathology open environment with the integration of more than 20 advanced artificial intelligence (AI) algorithms from eight new collaborators. These strategic collaborations aim to support pathologists and scientists in cancer research and diagnosis by leveraging cutting-edge AI technology.

Read More
Roche Holding
Technical Analysis Termsheet Terminal
Permalink
Tue, 30.01.2024       Roche Holding
US7711951043

LONDON, 30. Januar 2024 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY), eines der weltweit größten Pharmaunternehmen, wurde mit der IDC-Auszeichnung Future Enterprise Best in Future of Intelligence EMEA für seine Enterprise Self-Service-Datenplattform ausgezeichnet, die Immuta® für den Datenschutz und die fein abgestufte Zugriffskontrolle sowohl auf zentraler als auch auf Domänenebene nutzt. IDC ist ein weltweit führender Anbieter von Marktinformationen und Beratungsdiensten. Mit der Auszeichnung werden Unternehmen gewürdigt, die in den Bereichen Innovation, digitale Transformation und betriebliche Exzellenz führend sind. Im ersten Jahr seines Bestehens wurden für das Programm Bewerbungen aus über 15 Branchen und von über 600 Unternehmen eingereicht.

Read More
Roche Holding
Technical Analysis Termsheet Terminal
Permalink
Thu, 26.10.2023       Roche Holding
US7711951043

Roche's navify Digital Pathology software platform now offers Ibex's Artificial Intelligence (AI) algorithms to support clinicians in the diagnosis of breast and prostate cancer. Roche and Ibex cloud-based digital pathology and AI solutions run on Amazon Web Services (AWS), enabling a scalable and sustainable ecosystem for pathology laboratories.This collaboration builds on Roche's Digital Pathology Open Environment on the navify platform, expanding the company's commitment to improving patient care and advancing personalised healthcare through innovation.
Read More
Roche Holding
Technical Analysis Termsheet Terminal
Permalink
Tue, 05.09.2023       Roche Holding
US7711951043

The report shows digital health technologies demonstrate value, yet integrating them into care systems remains challenging. Involving healthcare professionals and patients in technology design and development is also critical for patient-centred care.1The report surveyed 10 countries, all of which have some foundations in place to use digital health technologies, such as regulatory frameworks and interoperability standards.The report illustrates additional challenges, such as fragmented national-level electronic health record systems and a lack of established health technology assessment (HTA) mechanisms for digital tools in some countries.2
Read More
Roche Holding
Technical Analysis Termsheet Terminal
Permalink
Tue, 05.09.2023       Roche Holding
US7711951043

The report shows digital health technologies demonstrate value, yet integrating them into care systems remains challenging. Involving healthcare professionals and patients in technology design and development is also critical for patient-centred care.1The report surveyed 10 countries, all of which have some foundations in place to use digital health technologies, such as regulatory frameworks and interoperability standards.The report illustrates additional challenges, such as fragmented national-level electronic health record systems and a lack of established health technology assessment (HTA) mechanisms for digital tools in some countries.2
Read More
Roche Holding
Technical Analysis Termsheet Terminal
Permalink
Tue, 05.09.2023       Roche Holding
US7711951043

The report shows digital health technologies demonstrate value, yet integrating them into care systems remains challenging. Involving healthcare professionals and patients in technology design and development is also critical for patient-centred care.1The report surveyed 10 countries, all of which have some foundations in place to use digital health technologies, such as regulatory frameworks and interoperability standards.The report illustrates additional challenges, such as fragmented national-level electronic health record systems and a lack of established health technology assessment (HTA) mechanisms for digital tools in some countries.2
Read More
Roche Holding
Technical Analysis Termsheet Terminal
Permalink
Tue, 05.09.2023       Roche Holding
US7711951043

The report shows digital health technologies demonstrate value, yet integrating them into care systems remains challenging. Involving healthcare professionals and patients in technology design and development is also critical for patient-centred care.1The report surveyed 10 countries, all of which have some foundations in place to use digital health technologies, such as regulatory frameworks and interoperability standards.The report illustrates additional challenges, such as fragmented national-level electronic health record systems and a lack of established health technology assessment (HTA) mechanisms for digital tools in some countries.2
Read More
Roche Holding
Technical Analysis Termsheet Terminal
Permalink
Tue, 05.09.2023       Roche Holding
US7711951043

The report shows digital health technologies demonstrate value, yet integrating them into care systems remains challenging. Involving healthcare professionals and patients in technology design and development is also critical for patient-centred care.1The report surveyed 10 countries, all of which have some foundations in place to use digital health technologies, such as regulatory frameworks and interoperability standards.The report illustrates additional challenges, such as fragmented national-level electronic health record systems and a lack of established health technology assessment (HTA) mechanisms for digital tools in some countries.2
Read More
Roche Holding
Technical Analysis Termsheet Terminal
Permalink
Sable Offshore
INVESTIGATION ALERT: Edelson Lechtzin LLP Announces an Investigation of Sable Offshore Corp. (NASDAQ: SOC) and Encourages Investors with Substantial Losses to Contact the Firm
© PR Newswire
Reddit
RDDT Investors Have Opportunity to Lead Reddit, Inc. Securities Fraud Lawsuit
© PR Newswire
Red Cat
RCAT Investors Have Opportunity to Lead Red Cat Holdings, Inc. Securities Fraud Lawsuit
© PR Newswire
TechTarget
Rosen Law Firm Encourages TechTarget, Inc. Investors to Inquire About Securities Class Action Investigation - TTGT
© PR Newswire
PepGen
PEPG Investors Have Opportunity to Lead PepGen Inc. Securities Fraud Lawsuit
© PR Newswire
Omnicom Group
Omnicom Networks Win Top Honors at Cannes Lions 2025
© PR Newswire
DoubleVerify
DV Investors Have Opportunity to Lead DoubleVerify Holdings, Inc. Securities Fraud Lawsuit
© PR Newswire
Organon & Co.
OGN Investors Have Opportunity to Lead Organon & Co. Securities Fraud Lawsuit
© PR Newswire
Lument Finance Trust
Lument Finance Trust, Inc. Declares Quarterly Cash Dividends for its Common and Preferred Stock
© PR Newswire
Africa Energy
Africa Energy Announces Annual Meeting Voting Results
© PR Newswire
West Pharmaceutical
WST Deadline: WST Investors Have Opportunity to West Pharmaceutical Services, Inc. Securities Fraud Lawsuit
© PR Newswire
Pizza Pizza Royalty
PIZZA PIZZA ROYALTY CORP. ANNOUNCES JUNE DIVIDEND
© PR Newswire
NextEra Energy
NextEra Energy to meet with investors throughout June
© PR Newswire
Uranium Energy
Uranium Energy Corp Increases Holdings in Anfield Energy
© PR Newswire
Uranium Energy
Uranium Energy Corp Increases Holdings in Anfield Energy
© PR Newswire
HLS Therapeutics Inc.
HLS Therapeutics Reports Annual Meeting Results
© PR Newswire
NaaS Technology
NaaS Technology Inc. Received Nasdaq Notification Regarding Minimum Market Value Deficiency
© PR Newswire
Parke Bancorp Inc
PARKE BANCORP, INC. ANNOUNCES CASH DIVIDEND
© PR Newswire
BorgWarner
Webcast Alert: BorgWarner 2025 Second Quarter Results Conference Call
© PR Newswire
American Healthcare REIT
American Healthcare REIT Declares Second Quarter 2025 Distribution
© PR Newswire
Thinkific Labs
Thinkific Announces Results of Annual General Meeting of Shareholders
© PR Newswire
Defi Technologies
DeFi Technologies Engages ShareIntel and Urvin to Enhance Market Transparency and Shareholder Intelligence
© PR Newswire
Defi Technologies
DeFi Technologies Engages ShareIntel and Urvin to Enhance Market Transparency and Shareholder Intelligence
© PR Newswire
InnoCan Pharma
Innocan Pharma Announces Presentation of Narrative Review on Long-Acting Synthetic Cannabidiol for Chronic Pain at PAINWEEK Conference
© PR Newswire
InnoCan Pharma
Innocan Pharma Announces Presentation of Narrative Review on Long-Acting Synthetic Cannabidiol for Chronic Pain at PAINWEEK Conference
© PR Newswire

The information provided here is not subject to any editorial processing. It is prepared fully automatically and enriched with additional information and further research options. The aim of the content is to provide information seekers with the relevant information quickly and easily. A link back to the information provider and owner ensures that the data prepared here can be compared with the source information if required. The newsboard does not show information in real time. Please contact the exchange operator for this information if required. There is no claim to completeness. High availability cannot be guaranteed. If you notice any errors in the functionality, please let us know using the "Report a Bug" form below.

RAW DATA PROCESSING means that raw data is processed without changing the content. The data is supplemented to improve the interpretation of the information in terms of usability.

Note: The newswire cross-link panel at the top allows you to quickly and easily access additional sources of information. In the terminal view, the news is filtered at company level and enables targeted searches.

On behalf of the trading community, we would like to thank the operators of the trading venues for providing information services.